'Vapo' is Generic and Descriptive, No Monopoly for P&G: Madras High Court Upholds IPI India's Trademarks

Introduction

In a significant ruling for trademark law in India, the Madras High Court has dismissed petitions filed by global giant The Procter & Gamble Company (P&G) seeking the cancellation of trademarks held by IPI India Private Limited for products like "VAPORIN" and "VAPORIN COLD RUB." Delivered on January 6, 2026, by Justice N. Senthilkumar in O.P.(TM) Nos. 48, 49, and 50 of 2024, the decision underscores that the prefix "Vapo," derived from "vapour," is a descriptive term common to the trade and cannot be monopolized by P&G's well-known "VICKS VAPORUB" brand. The court found no deceptive similarity between the marks, emphasizing the need to evaluate trademarks as a whole without dissecting non-distinctive elements.

P&G, arguing under Sections 47, 57, and 125 of the Trade Marks Act, 1999, claimed that IPI's marks infringed upon its longstanding rights in "VAPORUB" and related "VAPO"-formative marks, alleging dishonest adoption to exploit goodwill built since the brand's launch in India in 1964. IPI countered that "Vapo" is publici juris—belonging to the public domain—and highlighted its honest use since 2013, supported by registrations and extensive marketing. The Registrar of Trade Marks was also named as a respondent. This verdict reinforces protections for descriptive terms in pharmaceutical and medicinal product branding, potentially impacting how multinational brands enforce IP rights against smaller competitors in descriptive sectors.

Case Background

The Procter & Gamble Company, founded in 1837 and a leader in health care and personal hygiene products, has long championed its "VICKS" brand, launched internationally in 1890 and in India in 1964. "VICKS VAPORUB," a flagship vapor-based ointment for cold relief, has garnered immense reputation and judicial protection. P&G holds multiple registrations for "VICKS," "VAPORUB," and variations like "VAPOCOOL" and "VAPOINHALER" across Classes 3 and 5, dating back to 1954. These marks are not only statutorily protected but also recognized as well-known under Indian law, with copyrights in distinctive packaging featuring blue-and-white trade dress.

The dispute arose when P&G discovered IPI India Private Limited marketing similar vapor-action products under "VAPORIN," "VAPORIN COLD RUB," and "Vapor In, Stress Out. Anytime, Anywhere." IPI, based in Telangana, has used these marks since 2013 for balms, rubs, and aromatherapy gels in Classes 3 and 5. It secured registrations: No. 3461733 (Class 3, 2017), No. 3897775 (Class 3, 2018), and No. 4285435 (Class 5). Evidence showed IPI's sales invoices across India, advertisements in metro trains, and online promotions, demonstrating established market presence without prior challenge from P&G.

In September 2022, P&G issued a cease-and-desist notice, alleging visual, phonetic, and conceptual similarity, plus trade dress imitation, intended to ride on "VICKS" goodwill. When IPI refused, P&G filed rectification petitions in the Madras High Court to remove IPI's registrations, invoking Sections 47 (non-use/removal for invalidity), 57 (rectification on absolute/relative grounds), and 125 (procedure). The cases were heard together, with arguments focusing on deceptive similarity under Sections 9 and 10 of the Act. No interim relief was sought, and the matter proceeded to a final hearing reserved on November 28, 2025.

This timeline highlights a classic IP clash: a multinational enforcing transborder reputation against a domestic player claiming honest concurrent use. The legal questions centered on whether "VAPORIN" deceptively resembled "VAPORUB," if "Vapo" warranted exclusive protection, and whether IPI's adoption was mala fide.

Arguments Presented

P&G, represented by counsel Abishek Jenasenan, mounted a robust case emphasizing prior rights and potential consumer confusion. They asserted "VICKS" as a house mark, with "VAPORUB" as an independent, distinctive identifier for vapor rubs, registered since 1977. Phonetically, visually, structurally, and conceptually, "VAPORIN" mirrored "VAPORUB," especially in the shared "VAPO" prefix, likely to confuse average consumers with imperfect recollection. P&G stressed identical trade channels—pharmacies and over-the-counter sales—and products for cold relief, heightening passing-off risks.

The multinational highlighted dishonest intent, claiming IPI copied trade dress (jar size, blue hues) to parasitize goodwill from decades of advertising. Dissection was rejected by P&G instead, holistic comparison showed overall similarity, per precedents like Amritdhara Pharmacy v. Satya Deo Gupta (1963), where phonetic resemblance in medicinal names warranted protection. Similarly, Parle Products v. J.P. & Co. (1972) supported viewing wrappers and impressions broadly. P&G invoked Sections 9(2)(a) (deception/confusion) and 10 (infringement), arguing "Vapo" had acquired secondary meaning through use, not mere descriptiveness. They dismissed third-party "Vapo" uses as irrelevant, given "VICKS VAPORUB's" dominance, and sought costs.

IPI, through counsel Ramesh Ganapathy, vigorously opposed, insisting marks be assessed whole under Section 17(2), not dissected. "VAPORIN" differed phonetically ("-rin" vs. "-rub") and visually (unique bottle designs, green accents vs. P&G's blue), with "VICKS" absent, preventing association. "Vapo" was descriptive of vapor-based preparations, an abbreviation of "vapour," publici juris, and common to trade—evidenced by 75+ words starting with "Vapo" and numerous third-party marks like "VAPORIZING Chest Rub" and "Vapocaps."

IPI showcased prior honest adoption since 2013, with global registrations (e.g., Dr. S. Wong's VAPORIN) and no P&G objection for years, implying acquiescence under Section 33. Sales data, ads, and invoices proved distinct identity. They cited F. Hoffmann-La Roche v. Geoffrey Manners (1969) for ignoring common descriptive suffixes in pharma names, and J.R. Kapoor v. Micronix India (1994) where "micro" as descriptive negated monopoly. Cadila Healthcare v. Gujarat Co-operative (2008) and Schering Corporation v. Alkem Laboratories (2009) reinforced that publici juris terms like ingredients can't be exclusively claimed. IPI argued P&G's delay barred relief and urged rejection to avoid stifling competition.

Legal Analysis

Justice Senthilkumar's reasoning pivoted on holistic trademark evaluation, rejecting P&G's dissection of "Vapo" while applying Sections 9, 10, and 17 of the Trade Marks Act, 1999. The court clarified that registration confers rights only to the mark as a whole; non-distinctive, common elements like "Vapo"—descriptive of vapor action—grant no exclusivity (Section 17(2)(b)). Precedents aligned with this: P&G's relied Amritdhara and Parle Products stressed overall similarity in non-descriptive contexts, but facts here mirrored IPI's citations where descriptiveness prevailed.

In Hoffmann-La Roche , the Supreme Court held common suffixes like "Vit" (for vitamins) ignorable, focusing on distinctive parts; similarly, "Mero" from "Meropenem" was publici juris in Astrazeneca UK Ltd. v. Orchid Chemicals (2007, Delhi HC), reducing confusion in pharma sales via prescriptions or informed dealers. J.R. Kapoor dismissed "micro" monopoly in electronics, as descriptive of technology. Cadila allowed "Sugar Free" descriptively despite secondary meaning, balancing monopoly avoidance with fair trade. Schering echoed that generic prefixes from active ingredients can't be owned exclusively.

The court distinguished: While "VICKS VAPORUB" enjoys well-known status, "VAPORUB" itself comprises descriptive "vapour" + "rub," not invented. Visuals differed—P&G's blue jar vs. IPI's roll-on/green gel—no trade dress imitation. Phonetics ("Vaporin" vs. "Vaporub") and structures diverged, unlikely to confuse average buyers. Third-party evidence (e.g., "Mentholatum Vapour Rub," "Snufflebabe Vapour Rub") proved "Vapo/Vapour" commonality, per Section 34 (saving prior vested rights). No mala fides: IPI's decade-long unchallenged use evidenced honesty.

This analysis aligns with evolving IP jurisprudence favoring competition over overbroad claims, especially in descriptives. Unlike Indian Hotels v. Jiva Institute (2008, Delhi HC), where self-registered descriptives barred denial, here P&G lacked "Vapo" standalone registration. The ruling clarifies: Secondary meaning doesn't elevate descriptives to protect against non-confusing uses, impacting pharma/cosmetics where functional terms abound.

Key Observations

The judgment extracts pivotal language emphasizing descriptiveness and holistic comparison:

• On "Vapo's" nature: "The term VAPO is merely an abbreviation of the word vapour and it is descriptive and common to the trade."

• On public domain status: "The term 'VAPO' is publici juris and as such the use of the word 'VAPO' in the 1st Respondent's mark will not render it deceptively similar to that of the petitioner's mark."

• On comparison method: "When the rival marks are taken as a whole and compared without any dissection or meticulous comparison, the marks are not similar and it cannot be stated that the product of the first respondent will create a doubt or impression to an average man with ordinary intelligence and imperfect recollection."

• On intention and evidence: "The documents produced... would show that 75 other products beginning with the name 'VAPO' are available in the market and it is common to the trade. Therefore, it cannot be said that there is a dishonest intention on the part of the first respondent."

These observations, drawn from paragraphs 25-26, highlight the court's empathetic view toward smaller entities, preventing giants from claiming generic prefixes.

Court's Decision

The Madras High Court unequivocally dismissed all three original petitions on January 6, 2026, refusing rectification of IPI's registrations and denying costs to P&G. No orders were passed against the Registrar. The ruling: Rival marks "VICKS VAPORUB" and "VAPORIN" et al. are neither deceptively similar nor phonetically/visual confusing; "Vapo" remains publici juris, unmonopolizable.

Implications are profound for IP practice. Multinationals must prove beyond descriptiveness for protection, especially in functional goods like vapor rubs, where consumers rely on distinctives like "VICKS." This curbs overreach, fostering innovation—smaller firms like IPI can use common terms honestly without fear of cancellation. Future cases may cite this for pharma disputes, emphasizing evidence of third-party use and market reality over isolated goodwill claims.

Practically, it signals caution in cease-and-desist strategies; delayed action may imply acquiescence. For legal professionals, it bolsters defenses under Section 17, promoting fair competition per Trade Marks Act aims. Broader effects: Enhanced clarity on "publici juris" in globalized markets, potentially reducing frivolous rectifications and easing Registry burdens. As vapor-based products proliferate, this decision ensures descriptive freedom, balancing IP incentives with public access.